(NASDAQ: MRVI) Maravai Lifesciences Holdings's forecast annual revenue growth rate of 9.23% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.63%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.33%.
Maravai Lifesciences Holdings's revenue in 2026 is $185,743,000.On average, 12 Wall Street analysts forecast MRVI's revenue for 2026 to be $53,688,493,492, with the lowest MRVI revenue forecast at $50,727,078,864, and the highest MRVI revenue forecast at $56,225,747,170. On average, 12 Wall Street analysts forecast MRVI's revenue for 2027 to be $57,930,102,985, with the lowest MRVI revenue forecast at $54,719,333,132, and the highest MRVI revenue forecast at $61,541,897,735.
In 2028, MRVI is forecast to generate $62,238,549,961 in revenue, with the lowest revenue forecast at $57,565,067,501 and the highest revenue forecast at $65,212,817,951.